
HCG Launches Rs 129 Crore Cancer Hospital in Hebbal
To begin with, HealthCare Global Enterprises (HCG) recently inaugurated the state-of-the-art HCG Hebbal cancer hospital in North Bengaluru. This newly built facility marks a major advancement in Indian oncology by bringing precise treatment options closer to local residents.
Technology Integration at HCG Hebbal Cancer Hospital
Specifically, the facility features Karnataka's very first Elekta Unity MR-Linac machine. Consequently, clinicians can now perform highly precise, adaptive radiation therapy by combining high-quality MRI imaging with a linear accelerator. Furthermore, this dual capability allows real-time visualization of tumors during treatment. Consequently, doctors can target cancer cells while sparing surrounding healthy tissues.
Additionally, the center offers other elite diagnostic tools. For example, it includes an 80-slice Digital PET-CT scanner and Accuray TomoTherapy. As a result, the medical team can deliver highly personalized oncology services. Therefore, patients receive customized care plans that maximize treatment efficacy.
A Robust Clinical Infrastructure
Notably, the hospital houses up to 132 beds to accommodate diverse patient needs. In addition, the facility contains five advanced robotic-assisted operation theatres. These surgical suites enable complex, minimally invasive procedures. Furthermore, patients have access to 19 chemotherapy daycare beds and 14 premium treatment bays.
Meanwhile, a dedicated 15-bed intensive care unit supports critically ill individuals. The hospital also provides comprehensive endoscopy, mammography, and histopathology services. Consequently, patients can access complete, full-spectrum oncology care under one roof without visiting multiple locations. Thus, HCG continues to expand its clinical footprint in South India.
Strategic Investment and Corporate Growth
Financially, HCG funded this Rs 129 crore project using a strategic mix of debt and internal accruals. This launch follows a major investment by KKR, which previously acquired a 54% stake in the company. Currently, the healthcare provider operates roughly 2,500 beds across 25 cancer centers in India.
Additionally, reports suggest that HCG is negotiating to acquire American Oncology from Siemens Healthineers. This acquisition would expand the chain’s presence even further. However, the immediate focus remains on maximizing local patient outcomes at the new Hebbal center. Through these efforts, HCG aims to make advanced, metastatic cancers highly manageable.
Frequently Asked Questions
Q1: What advanced technology is available at the HCG Hebbal cancer hospital?
The facility features Karnataka's first Elekta Unity MR-Linac, which combines precise high-quality MRI imaging with a linear accelerator for adaptive radiation therapy.
Q2: How many beds are available in this new healthcare facility?
The newly launched comprehensive cancer center in Hebbal, Bengaluru provides up to 132 patient beds, including a 15-bed ICU.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
- HCG opens new Bengaluru facility with Rs 129 crore investment - ETHealthworld
- HCG invests ₹129 crore in new 132-bed Bengaluru hospital featuring advanced MR-LINAC technology - Sahi
- HCG Cancer Hospital Hebbal - HCG Oncology

More from MedShots Daily

HealthCare Global (HCG) has launched a new 132-bed cancer hospital in Hebbal, Bengaluru with a Rs 129 crore investment and advanced MR-Linac technology....
Yesterday

UK Biobank findings reveal that abdominal aortic calcification is independently associated with poor muscle composition and a higher risk of incident falls....
Today

A study identifies placenta previa and ultrasound suspicion as major predictors for intraoperative blood transfusion in placenta accreta spectrum management...
Today

Procizumab is a humanized antibody that neutralizes circulating DPP3, a biological driver of shock, by preventing angiotensin II degradation....
Today

Medtronic has announced its plans to acquire SPR Therapeutics for $650 million, expanding its non-opioid, minimally invasive chronic pain treatments....
Today

Two-year results from the PaTHway trial show that palopegteriparatide improves eGFR and reduces reliance on conventional therapy in chronic hypoparathyroidi...
Today